Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Trial Details

NCT ID
NCT06001788
Phase
PHASE1
Sponsor
Kura Oncology, Inc.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ziftomenib
  • Fludarabine
  • Idarubicin
  • Cytarabine
  • Gilteritinib
  • Granulocyte colony-stimulating factor
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311
  • San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

  • Has been diagnosed with relapsed/refractory AML.
  • Has a documented NPM1 mutation or KMT2A rearrangement.
  • Has a documented FLT3 mutation (cA-3 only).
  • Has an Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →